Literature DB >> 24200402

Current surgical therapy for bronchiectasis: surgical results and predictive factors in 86 patients.

Akın Eraslan Balci1, Tansel Ansal Balci2, Mehmet Oğuzhan Ozyurtan3.   

Abstract

BACKGROUND: This study retrospectively evaluated the surgical indications and outcomes of 86 patients with bronchiectasis.
METHODS: Between 2000 and 2013, the clinical and surgical specifications as well as follow-up results of patients with bronchiectasis were reviewed. Cystic and cylindric morphologic features were determined by chest computed tomography and hemodynamics (perfused and nonperfused), by lung ventilation/perfusion scans. The main indication for surgical resection was localized areas of cystic, nonperfused bronchiectasis.
RESULTS: Patients were a mean age of 37.8 ± 14.5 years. Symptom duration was 43.4 ± 36.9 months. Bronchiectasis was saccular in 66 patients (76.7%) and varicose in 20 (23.3%). Localized defects were limited in one region of the lung in 53 (61.6%), and 54 (62.8%) showed a mixed or an obstructive ventilatory pattern. Failure of medical therapy was the most common indication for pulmonary resection. The 86 patients underwent 98 operations. Ten underwent staged thoracotomies (contralateral lobectomy, 7; contralateral segmentectomy, 3). Complete resection of all bronchiectatic areas was done in 78 patients (90.7%). Complications developed in 14 patients (14.6%). The mortality rate was 1.1% (n = 1). After surgical treatment, 71 of 86 patients (82.5%) were free of symptoms (excellent), and the remaining 15 (17.5%) had a reduction in preoperative symptoms. The 53 patients with localized perfusion defects underwent complete resection and had symptom-free (excellent) postoperative results. Complete resection independently predicted symptom-free outcome (p < 0.05); a forced expiratory volume in 1 second of less than 60% of the predicted value, an incomplete resection, and a preoperative antibiotic therapy independently predicted postoperative complications (p < 0.05).
CONCLUSIONS: Bronchiectasis can be improved with operation. In properly selected patients, pulmonary resection can be done with acceptable morbidity and mortality rates and can lead to lasting symptomatic improvements.
Copyright © 2014 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  11

Mesh:

Year:  2013        PMID: 24200402     DOI: 10.1016/j.athoracsur.2013.09.013

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Surgical management of non-cystic fibrosis bronchiectasis.

Authors:  Miyako Hiramatsu; Yuji Shiraishi
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Lung or liver: An imaging dilemma on Tc-99m macroaggregated albumin lung perfusion scintigraphy.

Authors:  Tarun Kumar Jain; Rohit Kumar Phulsunga; Sunil Kumar; Ashwani Sood; Anish Bhattacharya; Bhagwant Rai Mittal
Journal:  Indian J Nucl Med       Date:  2015 Oct-Dec

Review 3.  Efficiency and safety of surgical intervention to patients with Non-Cystic Fibrosis bronchiectasis: a meta-analysis.

Authors:  Li-Chao Fan; Shuo Liang; Hai-Wen Lu; Ke Fei; Jin-Fu Xu
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

4.  The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Authors:  Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti
Journal:  Ann Thorac Med       Date:  2017 Jul-Sep       Impact factor: 2.219

Review 5.  The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies.

Authors:  Kui Li; Li Liu; Yan Ou
Journal:  J Cardiothorac Surg       Date:  2022-10-11       Impact factor: 1.522

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.